Delving into the Latest Updates on Resistentia Pharmaceuticals AB with Synapse

概览

关联

2

项与 Resistentia Pharmaceuticals AB 相关的临床试验

EUCTR2007-006551-39-SE

/ Not yet recruitingN/A

A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients

开始日期2008-01-23

申办/合作机构

Resistentia Pharmaceuticals AB

NCT00439621

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients

The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.

开始日期2007-02-01

申办/合作机构

Resistentia Pharmaceuticals AB

100 项与 Resistentia Pharmaceuticals AB 相关的临床结果

登录后查看更多信息

0 项与 Resistentia Pharmaceuticals AB 相关的专利（医药）

登录后查看更多信息

100 项与 Resistentia Pharmaceuticals AB 相关的药物交易

登录后查看更多信息

100 项与 Resistentia Pharmaceuticals AB 相关的转化医学

登录后查看更多信息